Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 8Tumor-Agnostic 1Thoracic 1Other neoplasm 1Other 1Head & Neck 1Gastrointestinal 1

Conditions

Intrathecal Dexmedetomidine 1

Interventions

Cyclophosphamide 7fludarabine phosphate 6Peripheral Blood Stem Cell Transplantation 6Whole-Body Irradiation 5Tacrolimus 4Mycophenolic Acid 4Methotrexate 4Melphalan 4Busulfan 4Sulindac 3Paclitaxel 3Cyclosporine 3Cisplatin 3Capecitabine 3Biopsy 3Antilymphocyte Serum 3toripalimab 2sintilimab 2fludarabine 2Taxes 2Surveys and Questionnaires 2Specimen Handling 2Sirolimus 2Radiotherapy 2Patient Reported Outcome Measures 2Nivolumab 2Mesna 2Magnetic Resonance Spectroscopy 2Hyperthermic Intraperitoneal Chemotherapy 2Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Bupivacaine × Other neoplasm × Clear all
NCT02861716 2018-04-10

Intrathecal Dexmedetomidine Versus Fentanyl With Bupivacaine in Children Undergoing Major Abdominal Cancer Surgery

South Egypt Cancer Institute

Phase 2 Unknown
60 enrolled
Other neoplasm

Intrathecal Dexmedetomidine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡